- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452994
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
June 12, 2025 updated by: Janssen Research & Development, LLC
Individual Patient IND Expanded Access Program JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Patient J.M. With Multiple Myeloma
The purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization.
Such access may be considered for participants with serious/life-threatening diseases or conditions, where there exists no alternative treatments or where alternative treatments have been exhausted.
Study Overview
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 26, 2020
First Submitted That Met QC Criteria
June 26, 2020
First Posted (Actual)
July 1, 2020
Study Record Updates
Last Update Posted (Actual)
June 13, 2025
Last Update Submitted That Met QC Criteria
June 12, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CR108848
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Zhongshan Hospital (Xiamen), Fudan UniversityNot yet recruitingMultiple Myeloma Progression | Multiple Myeloma Refractory
-
University Health Network, TorontoRecruitingMultiple Myeloma in Relapse | Multiple Myeloma RefractoryCanada
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
PETHEMA FoundationNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Tongji Hospital; Jinhua Municipal Central Hospital; Taizhou Hospital of Zhejiang...RecruitingRelapse Multiple MyelomaChina
-
Guangzhou Bio-gene Technology Co., LtdWithdrawnMultiple Myeloma Refractory
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on JNJ-68284528
-
Janssen Research & Development, LLCCompleted
-
Janssen Scientific Affairs, LLCAvailableMultiple MyelomaUnited States, Germany
-
Janssen Research & Development, LLCRecruitingMultiple MyelomaUnited States, Belgium, France, Netherlands, Spain, Israel, China, Japan
-
Peter MacCallum Cancer Centre, AustraliaJanssen, LPRecruiting
-
Janssen Research & Development, LLCRecruitingMultiple MyelomaUnited States, Australia, Spain
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Janssen Research & Development, LLCActive, not recruitingLymphoma, Non-HodgkinDenmark, Spain, Israel, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Scientific Affairs, LLCCompletedMultiple MyelomaUnited States
-
Janssen Research & Development, LLCActive, not recruitingMultiple MyelomaUnited States, Australia